Pryor Cashman represented Soleus as the lead investor in a notable late-stage $72.5 million financing of BioAtla, Inc., alongside a prominent roster of leading investment funds from the life sciences space, including HBM Healthcare Investments as co-lead, Cormorant Asset Management, Farallon Capital, Pappas Capital, funds managed by Janus Henderson, Boxer Capital, and an unnamed institutional investor. Current investor Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE), also participated in the financing.
The press release of the deal can be found here.
The Pryor Cashman team was led by Michael Weinsier, with principal assistance from associate Royce Liu. Partners Jeffrey Snow (IP) and Mike Dunworth (Tax), as well as associates Joseph Micali (IP), Taylor Weinstein (Tax), and Vedad Tabich (Corporate) also assisted in the deal.
About Soleus Capital
Soleus Capital Management, L.P. is a healthcare investment firm focused on the innovative areas of life sciences, including biotechnology, and medical technology. The firm's interest spans across the healthcare lifecycle from developmental-stage companies through commercial companies.
Originally published 15 July, 2020
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
